2 results about "PRIMARY BILIARY ATRESIA" patented technology

The present application relates to the technical field of vascular interventional treatment instruments, and discloses a system and method for the selective laser ablation of restenosis after the treatment of Budd-Chiari syndrome, comprising a controller, a pulse emission module and a reference element built into a catheter, the system is based on the reference element for periodic self-calibration, collects and processes the associated photoacoustic signals to identify the tissue type, and then realizes the selective ablation of the diseased tissue and the boundary self-stop when the healthy tissue is touched. The present application converts the traditional open-loop energy delivery into a closed-loop self-control process with real-time information interaction capability, so that the ablation operation end can in-situ perceive the tissue boundary and realize autonomous stop, thereby avoiding the problem of damaging the healthy tissue due to uncontrollable energy application, improving the safety of the operation, and having the advantages of high precision, few complications, repeatable treatment and the like.

This invention belongs to the field of biomedical technology, specifically relating to the application of spermine in the preparation of drugs for treating biliary atresia. This invention is the first to verify, through animal experiments (RRV mouse model), that spermine has a clear therapeutic effect on biliary atresia, achieving common bile duct recanalization and significantly reducing liver inflammation. Spermine itself possesses multiple functions including antioxidant, anti-inflammatory, and direct JAK1 inhibition, potentially working synergistically through multiple mechanisms such as mitigating initial damage and regulating immune responses, providing a more comprehensive pathological intervention than single-target inhibitors. Furthermore, spermine, as a known compound, has low production costs, and its application will greatly improve the accessibility of treatment.